Linked Data API

Show Search Form

Search Results

1124720
star this property registered interest false more like this
star this property date less than 2019-05-03more like thismore than 2019-05-03
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Idiopathic Pulmonary Fibrosis more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) early diagnosis and (b) treatment of idiopathic pulmonary fibrosis. more like this
star this property tabling member constituency Stevenage more like this
star this property tabling member printed
Stephen McPartland more like this
star this property uin 250788 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>The United Kingdom Rare Disease Strategy, published in 2013, sets out our commitment to raising awareness about all rare diseases including idiopathic pulmonary fibrosis (IPF) and our strategic vision for improving the lives of all those affected. The Strategy promotes improvements to ensure that people living with a rare disease receive high-quality care.</p><p>The Government recognizes the need for awareness raising and training of health care professionals for rare diseases. This is being taken forward through the work of the UK Rare Diseases Policy Board and NHS England’s Rare Diseases Implementation plan, which commits NHS England to engaging with the Royal College of General Practitioners (GPs) and the Nursing and Midwifery Council on opportunities for GPs and health visitors to recognise and facilitate earlier diagnosis of rare diseases.</p><p>There are limited drug treatment options for IPF and two drugs, Pirfenidone and Nintedanib, are commissioned following National Institute for Health and Care Excellence Technology Appraisals. Alongside this, the Department funds research into rare diseases such as IPF through the National Institute for Health Research (NIHR).</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:35:47.667Zmore like thismore than 2019-05-15T16:35:47.667Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4093
star this property label Biography information for Stephen McPartland more like this
1124901
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Nusinersen more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what discussions they have had with (1) NICE, (2) NHS England, and (3) Biogen, on a Managed Access Agreement for Spinal Muscular Atrophy treatment, Spinraza. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15576 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15577 more like this
star this property question first answered
less than 2019-05-17T11:07:46.62Zmore like thismore than 2019-05-17T11:07:46.62Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1124902
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government when they estimate that NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March. more like this
star this property tabling member printed
Baroness Thomas of Winchester more like this
star this property uin HL15577 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-17more like thismore than 2019-05-17
star this property answer text <p>Departmental officials are in regular contact with colleagues in the National Institute for Health and Care Excellence (NICE) and NHS England about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen). Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting and NICE is now able to recommend the use of Spinraza for National Health Service patients in England, subject to a managed access agreement agreed between NHS England and Biogen. The final appraisal document will be published in due course.</p><p> </p> more like this
unstar this property answering member printed Baroness Blackwood of North Oxford more like this
star this property grouped question UIN HL15576 more like this
star this property question first answered
less than 2019-05-17T11:07:46.673Zmore like thismore than 2019-05-17T11:07:46.673Z
star this property answering member
4019
star this property label Biography information for Baroness Blackwood of North Oxford more like this
star this property tabling member
3785
star this property label Biography information for Baroness Thomas of Winchester more like this
1124918
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that haemophilia patients receive (a) appropriate access to physiotherapy, (b) a regular clinical review, and (c) tailored dosing of treatments in accordance with NHS England’s service specification. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251321 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251322 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.547Zmore like thismore than 2019-05-15T16:14:44.547Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124919
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Commercial Medicines Unit’s national tender framework for factor VIII haemophilia products on patient access to extended half-life medicines. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251322 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251323 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.61Zmore like thismore than 2019-05-15T16:14:44.61Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124920
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood Diseases: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps he NHS England is taking to ensure that patients with bleeding disorders have adequate access to treatment options that meet individual patient need. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251323 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251324 more like this
star this property question first answered
less than 2019-05-15T16:14:44.657Zmore like thismore than 2019-05-15T16:14:44.657Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124921
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Haemophilia: Medical Treatments more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of the adequacy of the availability of Haemtrack in Haemophilia centres. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251324 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Regular clinical reviews of patients with severe and moderate haemophilia and access to physiotherapy services are specified within the service specification for haemophilia which is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/06/b05-haemophilia.pdf</a></p><p>In addition, the Haemophilia Quality Dashboard has a metric specifically in relation to the proportion of severe Haemophilia patients who have had an annual review. Where local commissioning teams are made aware that haemophilia patients do not have access to appropriate care then local action plans will be agreed to rectify this.</p><p>The service specification for haemophilia currently does not require that haemophilia patients receive tailored dosing of treatment. However, commissioners consider that this would represent good practice. NHS England has supported clinical teams to provide tailored dosing, within the parameters of the agreed commissioning criteria and guidelines, by making a wide range of products available for reimbursement.</p><p>To date, all licensed and currently marketed products for haemophilia are available for reimbursement. Some products have been limited to Haemophilia Comprehensive Care Centres due to specific requirements for supporting services and expertise (these are products for patients with inhibitors).</p><p>NHS England wants all patients with lifelong conditions to be engaged in the management of their condition. NHS England, in conjunction with the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), believes that tools like Haemtrack are useful in achieving this aim. NHS England is aware of evidence that indicates, but does not confirm, that patients who use Haemtrack have better clinical outcomes than patients who do not. NHS England supports UKHCDO via the National Haemophilia Database to provide further data and evidence demonstrating the value and clinical benefits of Haemtrack.</p><p>The Commercial Medicines Unit has two national framework agreements in place that provide access to recombinant factor VIII (rFVIII) haemophilia products. The one licensed Extended Half Life-Factor VIII product available in the UK has been funded since September 2016 and a significant number of patients are now treated with this product. NHS England and other UK Health Commissioners work closely with clinicians and patient representatives to ensure that the frameworks continue to meet clinical need whilst delivering good value to the National Health Service.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
251321 more like this
251322 more like this
251323 more like this
star this property question first answered
less than 2019-05-15T16:14:44.703Zmore like thismore than 2019-05-15T16:14:44.703Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124923
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Hospitals: Infectious Diseases more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231466 on Hospitals: Infectious Diseases, whether work of Public Health England will also include as assessment of the effect of changes to ophthalmic surgical practice on trends in the level of risk of infection rates in hospitals. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251326 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Public Health England does not currently include ophthalmic surgery as part of mandatory or voluntary surveillance of surgical site infections.</p> more like this
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:24:36.63Zmore like thismore than 2019-05-15T16:24:36.63Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124924
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Ophthalmic Services more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March 2019 to Question 231467 on Ophthalmic Services, whether he has made an assessment of the ability for clinicians to take into account patients’ wishes for concomitant treatment in relation to potential restrictions of the 2019/2020 NHS Tariff. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 251327 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>For the 2017/19 national tariff (which was set for two years), the prices for BZ91 were manually increased above the initially modelled level (based on 2014/15 reference costs) following feedback from the ophthalmology Expert Working Group (EWG). For 2019/20, the EWG recommended that the prices for BZ91 should not be increased and should remain as modelled (based on 2016/17 reference costs).</p><p>The EWG also confirmed that minimally invasive glaucoma surgery (MIGS) and cataract activity are commonly done together and it would not usually be in the patient’s best interest to do them separately. The EWG advised that BZ91 was appropriate for combined MIGS and cataract activity – a MIGS procedure plus a cataract procedure should not receive over twice as much as either procedure alone.</p> more like this
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:43:32.397Zmore like thismore than 2019-05-15T16:43:32.397Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4131
star this property label Biography information for Jim Shannon more like this
1124938
star this property registered interest false more like this
star this property date less than 2019-05-07more like thismore than 2019-05-07
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Health Education: Air Pollution more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what progress his Department is making on producing a public information campaign to educate the general public on the health impacts of air pollution, particularly in instances of moderate or high pollution episodes. more like this
star this property tabling member constituency Penistone and Stocksbridge more like this
star this property tabling member printed
Angela Smith more like this
star this property uin 251250 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-15more like thismore than 2019-05-15
star this property answer text <p>Public Health England and the Department for Environment, Food and Rural Affairs (Defra) are exploring whether social marketing can assist in awareness-raising about air pollution.</p><p>The Joint Air Quality Unit (JAQU) is planning a national-level campaign to support Clean Air Zones (CAZ) from summer 2019. This will raise awareness of the risks presented by high concentrations of nitrogen dioxide (NO2) and the implementation of charging CAZ. It will also promote long-term behaviour change by encouraging the public to change travel habits and reduce NO2 emissions.</p><p>The JAQU has also provided a CAZ communications toolkit to support local authorities in their local communications work. It contains key messages, frequently asked questions, useful statistics, infographics and other content to ensure a consistent approach is taken to raising awareness and to encourage drivers to consider alternative options in terms of travel and vehicle choice.</p><p>Defra is developing a communication strategy on domestic combustion for launch before the next winter burning season.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-15T16:30:01.73Zmore like thismore than 2019-05-15T16:30:01.73Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1564
star this property label Biography information for Angela Smith more like this